Physician profile
Thomas J Willke
NPI 1184617888
$10,116.19
in general payments reported to CMS, 2019-2025
51 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,259 · 2020: $661 · 2021: $941 · 2022: $1,527 · 2023: $1,858 · 2024: $2,172 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,727.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,424.69 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,193.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,092.23 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $700.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $628.59 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $623.21 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $467.76 | 2019-2025 | Gardasil 9, Capvaxive, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.85 | 2019-2024 | Jardiance, Stiolto Respimat, Tradjenta |
| Janssen Pharmaceuticals, INC | $434.04 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $359.87 | 2021-2025 | |
| Pfizer INC. | $308.95 | 2019-2025 | |
| Amgen INC. | $249.28 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $248.73 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $193.12 | 2019-2025 | |
| Exact Sciences Corporation | $163.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Willke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.